港股异动 | 荣昌生物(09995)再涨近8% 维迪西妥单抗多项原创研究成果在2026 EAU集中发布

智通财经03-18

智通财经APP获悉，荣昌生物(09995)再涨近8%，截至发稿，涨6.08%，报96.8港元，成交额2.38亿港元。消息面上，3月13日至16日，2026年欧洲泌尿外科协会(EAU)年会在英国伦敦举行。本届年会上，围绕HER2靶向抗体偶联药物(ADC)维迪西妥单抗在尿路上皮癌治疗中的创新应用，多项来自中国的前沿研究成果集中发布，覆盖了从早期到晚期、从膀胱癌到上尿路尿路上皮癌的全疾病谱，为尿路上皮癌...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620288926?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-18 10:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620288926","market":"us","top_or_hot":-1,"title":"港股异动 | 荣昌生物(09995)再涨近8% 维迪西妥单抗多项原创研究成果在2026 EAU集中发布","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，荣昌生物(09995)再涨近8%，截至发稿，涨6.08%，报96.8港元，成交额2.38亿港元。消息面上，3月13日至16日，2026年欧洲泌尿外科协会(EAU)年会在英国伦敦举行。本届年会上，围绕HER2靶向抗体偶联药物(ADC)维迪西妥单抗在尿路上皮癌治疗中的创新应用，多项来自中国的前沿研究成果集中发布，覆盖了从早期到晚期、从膀胱癌到上尿路尿路上皮癌的全疾病谱，为尿路上皮癌...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415242.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 荣昌生物(09995)再涨近8% 维迪西妥单抗多项原创研究成果在2026 EAU集中发布</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 荣昌生物(09995)再涨近8% 维迪西妥单抗多项原创研究成果在2026 EAU集中发布\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-18 10:13 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1415242.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，荣昌生物(09995)再涨近8%，截至发稿，涨6.08%，报96.8港元，成交额2.38亿港元。消息面上，3月13日至16日，2026年欧洲泌尿外科协会(EAU)年会在英国伦敦举行。本届年会上，围绕HER2靶向抗体偶联药物(ADC)维迪西妥单抗在尿路上皮癌治疗中的创新应用，多项来自中国的前沿研究成果集中发布，覆盖了从早期到晚期、从膀胱癌到上尿路尿路上皮癌的全疾病谱，为尿路上皮癌...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1415242.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1415242.html","article_id":"2620288926","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620288926","pubTimestamp":1773799996,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，荣昌生物再涨近8%，截至发稿，涨6.08%，报96.8港元，成交额2.38亿港元。值得注意的是，荣昌生物近日发布业绩快报，营业收入32.51亿元人民币，同比增加89.36%；归母净利润7.09亿元，同比扭亏为盈。营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加；此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术授权收入大幅增加。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688331":"荣昌生物","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","09995":"荣昌生物","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0239":"医药制造","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"Changes in Hong Kong stocks | Rongchang Biotech (09995) rose by nearly 8% again. Many original research results of vidicitumab were released in 2026 EAU","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1.5,"09995":1.5,"VXUS":1.5},"content_text":"智通财经APP获悉，荣昌生物(09995)再涨近8%，截至发稿，涨6.08%，报96.8港元，成交额2.38亿港元。消息面上，3月13日至16日，2026年欧洲泌尿外科协会(EAU)年会在英国伦敦举行。本届年会上，围绕HER2靶向抗体偶联药物(ADC)维迪西妥单抗在尿路上皮癌治疗中的创新应用，多项来自中国的前沿研究成果集中发布，覆盖了从早期到晚期、从膀胱癌到上尿路尿路上皮癌的全疾病谱，为尿路上皮癌的精准与器官保留治疗提供了强有力的新证据。值得注意的是，荣昌生物近日发布业绩快报，营业收入32.51亿元人民币，同比增加89.36%；归母净利润7.09亿元，同比扭亏为盈。营业收入增加主要是由于注射用泰它西普和注射用维迪西妥单抗销量增加，销售收入增加；此外，公司授予Vor Biopharma Inc.泰它西普除大中华区以外全球范围内的独家开发与商业化权利，技术授权收入大幅增加。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620288926","isCrawlerRequest":true}